Literature DB >> 22858832

Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment.

Marieke F Fransen1, Ramon Arens, Cornelis J M Melief.   

Abstract

In recent years, it has become apparent that immunoregulatory processes influence cancer development. The key players in tumor progression are mainly present in the microenvironment of the tumor and the draining lymph nodes. Interventions aimed at shifting tumor-promoting actions toward effective tumor-eradicating immunity are thus foremost required locally. As immune-modulating therapy has been shown to cause many adverse side effects when administered systemically, we strongly advocate the further development of local treatment for cancer immunotherapy.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22858832     DOI: 10.1002/ijc.27755

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

Authors:  Marieke F Fransen; Mark Schoonderwoerd; Philipp Knopf; Marcel Gm Camps; Lukas Jac Hawinkels; Manfred Kneilling; Thorbald van Hall; Ferry Ossendorp
Journal:  JCI Insight       Date:  2018-12-06

2.  Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size.

Authors:  Nathan Andrew Rohner; Susan Napier Thomas
Journal:  ACS Biomater Sci Eng       Date:  2016-11-18

3.  Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity.

Authors:  Yongkui Li; Min Fang; Jian Zhang; Jian Wang; Yu Song; Jie Shi; Wei Li; Gang Wu; Jinghua Ren; Zheng Wang; Weiping Zou; Lin Wang
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

4.  IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.

Authors:  Ana Vuletić; Irena Jovanić; Vladimir Jurišić; Zorka Milovanović; Srđan Nikolić; Igor Spurnić; Gordana Konjević
Journal:  Pathol Oncol Res       Date:  2018-06-11       Impact factor: 3.201

5.  Lymph node stroma join the cancer support network.

Authors:  Anne L Fletcher; Tracy S P Heng
Journal:  Cell Death Differ       Date:  2016-09-30       Impact factor: 15.828

Review 6.  Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.

Authors:  Geoffrey M Lynn; Richard Laga; Christopher M Jewell
Journal:  Cancer Lett       Date:  2019-06-08       Impact factor: 8.679

7.  Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.

Authors:  Laura Calomarde-Rees; Rosario García-Calatayud; Celia Requena Caballero; Esperanza Manrique-Silva; Víctor Traves; Zaida García-Casado; Virtudes Soriano; Rajiv Kumar; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

8.  Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model.

Authors:  Melisa B Nicoud; Mónica A Táquez Delgado; María de la Paz Sarasola; Agustina Vidal; Daniela Speisky; Graciela A Cremaschi; Helena A Sterle; Vanina A Medina
Journal:  Cancer Immunol Immunother       Date:  2020-07-22       Impact factor: 6.968

9.  CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients.

Authors:  Jiali Zhang; Jing Xu; Rong-Xin Zhang; Yi Zhang; Qing-Jian Ou; Jin-Qing Li; Ze-Zhou Jiang; Xiao-Jun Wu; Yu-Jing Fang; Limin Zheng
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

Review 10.  Synthetic immune niches for cancer immunotherapy.

Authors:  Jorieke Weiden; Jurjen Tel; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.